Basil Systems, a Boston, MA-based provider of an AI-powered product lifecycle intelligence platform for the life sciences industry, raised $11.5M in Funding.
The round was led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital.
The company intends to use the funds to expand its enterprise BasilIntel SaaS platform, product capabilities, and accelerate the deployment of data-driven insights across the pharma and medical device industry.
Led by CEO and Founder Anthony Cirurgiao, Basil Systems delivers an AI-powered SaaS platform improving how pharma and MedTech companies manage regulatory, clinical, and product lifecycle strategy. By structuring indexed database of regulatory, drug, device, and post-market data, it helps life sciences organizations accelerate development, reduce risk, and improve product performance.
Its platform is used for strategic product development, supply chain optimization, risk mitigation, and real-world evidence (RWE) analysis. It supports use cases across regulatory, clinical, quality, medical affairs, and commercial divisions to provide a unified system of record and intelligence.
FinSMEs
29/04/2025